Shortage of Penicillin G Benzathine Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Penicillin G Benzathine Injection, an anti-infective medication, is currently in shortage with limited availability from Pfizer Inc., affecting various injection presentations.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 8, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Penicillin G Benzathine Injection.
Shortage of Penicillin G Benzathine Injection
What's in Shortage
The generic drug Penicillin G Benzathine Injection, with brand name BICILLIN L-A, is in a current shortage. It is available in injection dosage form and belongs to the therapeutic category of Anti-Infective. The shortage status is current, with the initial posting date of 04/26/2023 and last updated on 03/27/2026.
Which Manufacturers Are Affected
The affected manufacturer is Pfizer Inc., which has limited availability for the following presentations:
- Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10): Limited Availability. Related info: Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay. Contact info: 844-646-4398
- Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10): Limited Availability. Related info: Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay. Contact info: 844-646-4398
- Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10): Limited Availability. Related info: Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay. Contact info: 844-646-4398
Why There's a Shortage
The reason for the shortage is listed as "Other." Manufacturer-specific notes indicate a Manufacturing Delay.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist or healthcare provider about the current availability and options. They can also contact the manufacturer for more details. Please remember that patients should consult their healthcare provider for any guidance and not make changes to their treatment plan without professional advice.
Source
This information is attributed to the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,897 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 8, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.